The role of c-MYC in gastric cancer prognosis: a Kaplan-Meier-derived patient data meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: c-MYC-negative tumors exhibited a markedly higher DSS compared to those with c-MYC-positive tumors (HR 3
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Patients with c-MYC-negative tumors exhibited a markedly higher DSS compared to those with c-MYC-positive tumors (HR 3.73; 95% CI, 2.22-6.26; p < 0.0001). [CONCLUSION] Our findings identify c-MYC as a significant prognostic biomarker for disease-specific survival in gastric cancer.
[BACKGROUND] Gastric cancer (GC) is the fifth leading cause of cancer-related death worldwide, with a median overall survival of approximately 12 months.
- p-value p ≤ 0.05
- p-value p < 0.00001
- 95% CI 5.74-13.56
APA
Moraes FCA, Tadeu Freitas Uchôa Matheus G, et al. (2026). The role of c-MYC in gastric cancer prognosis: a Kaplan-Meier-derived patient data meta-analysis.. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 31(1), 29-39. https://doi.org/10.1080/1354750X.2025.2611007
MLA
Moraes FCA, et al.. "The role of c-MYC in gastric cancer prognosis: a Kaplan-Meier-derived patient data meta-analysis.." Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, vol. 31, no. 1, 2026, pp. 29-39.
PMID
41457440
Abstract
[BACKGROUND] Gastric cancer (GC) is the fifth leading cause of cancer-related death worldwide, with a median overall survival of approximately 12 months. The proto-oncogene c-MYC is among the most frequently activated oncogenes, implicated in roughly 20% of all malignancies.
[METHODS] PubMed, Embase, and Web of Science were systematically searched for studies evaluating the association between c-MYC expression and (1) disease-specific survival (DSS) and (2) overall survival (OS). Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using a fixed-effects model. A two-sided p ≤ 0.05 was considered statistically significant.
[RESULTS] Across 15 studies encompassing 2,372 gastric cancer patients (802 c-MYC-positive; 410 male), male gender was strongly associated with c-MYC positivity (OR 8.83; 95% CI 5.74-13.56; p < 0.00001), as were deeper invasion (T3-T4 vs T1-T2: OR 0.38; 95% CI 0.24-0.60; p < 0.00001) and advanced stage (III-IV vs I-II: OR 2.69; 95% CI 1.71-4.23; p < 0.00001). Patients with c-MYC-negative tumors exhibited a markedly higher DSS compared to those with c-MYC-positive tumors (HR 3.73; 95% CI, 2.22-6.26; p < 0.0001).
[CONCLUSION] Our findings identify c-MYC as a significant prognostic biomarker for disease-specific survival in gastric cancer.
[METHODS] PubMed, Embase, and Web of Science were systematically searched for studies evaluating the association between c-MYC expression and (1) disease-specific survival (DSS) and (2) overall survival (OS). Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using a fixed-effects model. A two-sided p ≤ 0.05 was considered statistically significant.
[RESULTS] Across 15 studies encompassing 2,372 gastric cancer patients (802 c-MYC-positive; 410 male), male gender was strongly associated with c-MYC positivity (OR 8.83; 95% CI 5.74-13.56; p < 0.00001), as were deeper invasion (T3-T4 vs T1-T2: OR 0.38; 95% CI 0.24-0.60; p < 0.00001) and advanced stage (III-IV vs I-II: OR 2.69; 95% CI 1.71-4.23; p < 0.00001). Patients with c-MYC-negative tumors exhibited a markedly higher DSS compared to those with c-MYC-positive tumors (HR 3.73; 95% CI, 2.22-6.26; p < 0.0001).
[CONCLUSION] Our findings identify c-MYC as a significant prognostic biomarker for disease-specific survival in gastric cancer.
MeSH Terms
Humans; Stomach Neoplasms; Proto-Oncogene Proteins c-myc; Proto-Oncogene Mas; Prognosis; Male; Biomarkers, Tumor; Kaplan-Meier Estimate; Female
같은 제1저자의 인용 많은 논문 (3)
- Treatment With PD-1/PD-L1 Inhibitors for Kaposi Sarcoma:A Systematic Review and Meta-Analysis.
- Impact of helicobacter pylori infection status on outcomes among patients with gastric cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
- The role of CLDN18.2 in gastric cancer prognosis: a systematic review and meta-analysis.